Key result
In rats with heart failure after myocardial infarction, Ac-SDKP significantly decreased total collagen content from 23.7 to 15.0 microg/mg (prevention) and 22.6 to 14.4 microg/mg (reversal) (P<0.01).
Why the study?
Does Ac-SDKP reduce inflammation and fibrosis in rats with heart failure after myocardial infarction?
Does Ac-SDKP reduce inflammation and fibrosis in rats with heart failure after myocardial infarction?
Absolute Event Rate: 15% vs 23.7%
p-value: p=<0.01
Ac-SDKP demonstrates anti-inflammatory and antifibrotic effects in a rat model of post-MI heart failure, though it does not improve cardiac function.
No takes yet. Share an insight, caveat, or question.
Ac-SDKP attenuates experimental post-MI fibrosis; leaves open translation to human heart failure therapy.
Yang et al. (2003) studied Heart failure after myocardial infarction. Ac-SDKP vs. Control was evaluated on Total collagen content (p=<0.01). In rats with heart failure after myocardial infarction, Ac-SDKP significantly decreased total collagen content from 23.7 to 15.0 microg/mg (prevention) and 22.6 to 14.4 microg/mg (reversal) (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: